Impact of Manipulative Character of Direct-to-Consumer Promotion

2019 ◽  
pp. 198-211 ◽  
Author(s):  
Jaya Rani Pandey ◽  
Ajeya Jha ◽  
Saibal Kumar Saha
Keyword(s):  
Pharmaceutical Products ◽  
Direct Access ◽  
Healthcare Sector ◽  
Pharmaceutical Companies ◽  
Self Medication ◽  
Negative Perception ◽  
Legal Norms ◽  
Direct To Consumer ◽  
Poor Patient ◽  
Physician Relationship

Marketing of pharmaceutical products has remained under firm hold of ethical and legal norms. Direct advertising or any other form of direct promotion has been illegal in any or every country. Arrival of information technology, however, has ensured patients now have direct access to every possible detail of their ailments and their treatment through direct-to-consumer promotion (DTCP). Certain studies have shown that physicians consider DTCP to have manipulative character and are designed by pharmaceutical companies with ulterior motives. The aim is to explore relationship between manipulative character on self-medication propensity, negative perception, and poor patient-physician relationship as per the perception of physicians. With data from 218 physicians, insights into perceived manipulative character, self-medication propensity, negative perception, and poor patient-physician relationship have been achieved. The finding has important implications for regulatory bodies, pharmaceutical companies, and healthcare sector stakeholders.

An Empirical Note on Comparative Perceptions of Indian Patients and Physicians in Direct-to-Consumer Promotion of Pharmaceutical Products

2019 ◽  
pp. 128-153 ◽  
Author(s):  
Jaya Rani Pandey ◽  
Ajeya Jha ◽  
Samrat Kumar Mukherjee ◽  
Saibal Kumar Saha
Keyword(s):  
Factor Analysis ◽  
Regression Model ◽  
Pharmaceutical Products ◽  
Latent Factors ◽  
Direct To Consumer ◽  
Related Information ◽  
Health Related ◽  
Empirical Note ◽  
Physician Relationship ◽  
The Impact

Direct promotion of pharmaceutical products to patients is not legal in India. Internet healthcare websites, however, have rendered this law moot. Patients today increasingly flock to websites to find health-related information. With the help of a survey involving 400 patients and 200 physicians, this chapter attempts to identify the differences in the perception of physicians and patients. The results indicate that major differences exist in the beliefs held by physicians and patients vis-à-vis merits and demerits of DTC-promotion through health-related websites. As patients and physicians operate as a team while health-solutions are made available to the patients, such major differences in their beliefs regarding the merits and demerits of DTC-promotion may result in emergence of fault lines in their relationship. An exploratory factor analysis has been conducted to confirm if the underlying variables measure the latent factors or not. Regression model has been developed to measure the impact of information perception on patient-physician relationship.

Relationship between Cross-Border Mergers and Acquisitions and International Trade: The Case of Russian Pharmaceutical Industry

2020 ◽  
pp. 81-94
Author(s):  
Alexandra V. Chugunova ◽  
Olga A. Klochko
Keyword(s):  
International Trade ◽  
Mergers And Acquisitions ◽  
Volume Growth ◽  
Pharmaceutical Products ◽  
Pharmaceutical Companies ◽  
Cross Border ◽  
Export Volume ◽  
Relationship Of ◽  
Geographical Diversification ◽  
The Relationship

This research studies the relationship of cross-border mergers and acquisitions to international trade through the lens of Russian pharmaceutical market. To this aim, the study analyses the woks of foreign economists dedicated to evaluating the link between foreign direct investment and international trade, and the influence of mergers and acquisitions on countries’ export and import flows. The research also presents a correlation analysis between the volume of Russian pharmaceutical exports and imports and cross-border deals performed by foreign pharmaceutical companies in Russia. We characterize these deals and conduct a comparative analysis of the regional structure of Russian pharmaceutical exports and imports as well as of the countries of origin of buyers in cross-border mergers and acquisitions. The results of the analysis indicate a positive relationship between cross-border mergers and acquisitions and Russian pharmaceutical exports, which is reflected in the export volume growth and its geographical diversification. However, it is outlined that particular problems of the industry hinder the amelioration of Russian positions in international exports. Similarly, the relationship between cross-border deals and Russian imports is positive: the major pharmaceutical products supply flow occurs from the countries of origin of buyers in cross-border mergers and acquisitions conducted in the Russian pharmaceutical sector.

Fake Pharmaceuticals: How They and Relevant Legislation or Lack Thereof Contribute to Consistently High and Increasing Drug Prices

2003 ◽  
Vol 29 (4) ◽  
pp. 525-542
Author(s):  
Merri C. Moken
Keyword(s):  
United States ◽  
Prescription Drugs ◽  
The United States ◽  
Pharmaceutical Products ◽  
New Drugs ◽  
Pharmaceutical Companies ◽  
Brand Name ◽  
Potential Factors ◽  
Counterfeit Pharmaceuticals ◽  
New Applications

The use of pharmaceutical products in the United States has increased more than the use of any other health resource from 1960 to 1990. In excess of 9,600 drugs were on the market in 1984, and the Food and Drug Administration (“FDA”) approves approximately 30 new drugs and countless new applications for alterations of already existing drugs each year. In 2001, the $300 billion pharmaceutical industry sold $154 billion worth of prescription drugs in the United States alone, nearly doubling its $78.9 billion in sales in 1997. With such a rapid increase in market domination and expenditures, the U.S. government and many hospitals have focused their attention on the sales and pricing practices of pharmaceutical companies, as well as other potential factors contributing to these escalating prices. One such cause of the steadily increasing prices of brand name pharmaceuticals is the sale of fake or counterfeit pharmaceuticals (also called “look-alike” drugs).

Direct-to-Consumer Prescription Drug Advertising

1999 ◽  
Vol 25 (1) ◽  
pp. 149-167
Author(s):  
Tamar V. Terzian
Keyword(s):  
Prescription Drug ◽  
Drug Administration ◽  
Food And Drug Administration ◽  
Pharmaceutical Products ◽  
Drug Advertising ◽  
Direct To Consumer ◽  
Prescription Drug Advertising ◽  
Adequate Provision ◽  
Package Labeling ◽  
Made In

The Food and Drug Administration (FDA) regulates the promotion of pharmaceutical products. The FDA's regulations issued under the Food, Drug and Cosmetic Act (FDCA) require that prescription drug broadcast advertisements include the following: (1) a major statement of the product's risks in at least the audio part of the advertisement; and (2) that an adequate provision for the dissemination of the approved package labeling be made “in connection with the broadcast presentation,” if the brief summary is not also part of the advertisement. Under the FDCA, the brief summary provides information concerning the major risks of the drug.

Happy families in the pharmaceutical industry

1983 ◽  
Vol 21 (20) ◽  
pp. 77-79
Keyword(s):  
Pharmaceutical Industry ◽  
Pharmaceutical Products ◽  
Pharmaceutical Companies ◽  
Parent Companies

Many large pharmaceutical companies operate subsidiaries or divisions with separate names and identities. Some of these subsidiaries have been specially created while others are survivors, in name, of take-overs or mergers. This has led to an increase in the number of trading companies promoting pharmaceutical products and to the practice of transferring established products from the parent companies to their subsidiaries. The results of the proliferation and re-organisation of companies will affect prescribers.

scholarly journals Market Survey and Analysis of Packaging Information Provided by Different Pharmaceutical Companies of Bangladesh

2012 ◽  
Vol 15 (2) ◽  
pp. 165-169
Author(s):  
Shibtosh Sarker ◽  
Arindom Pal ◽  
Jesmin Sultana
Keyword(s):  
Pharmaceutical Journal ◽  
Pharmaceutical Products ◽  
Packaging Material ◽  
Pharmaceutical Companies ◽  
Packaging Materials ◽  
Clinical Parameters ◽  
Dhaka City ◽  
Market Survey

The purpose of the present study was to investigate whether or not the pharmaceutical companies of Bangladesh are providing all the necessary information and instructions in the packaging materials of pharmaceutical products which are available in Bangladesh. With this aim, the sample of secondary packaging material (cartons, labels, inserts or direction slips) of a total 150 products (from 50 generics) marketed by 15 pharmaceutical companies have been selected and were collected from different medical stores of Dhaka city. The packaging materials of the collected samples were then evaluated based on various regulatory and clinical parameters. It was found that some of the packaging materials of these selected pharmaceutical products lack several  important information in terms of clinical and regulatory parameters which limits the quality of these packaging materials. DOI: http://dx.doi.org/10.3329/bpj.v15i2.12585 Bangladesh Pharmaceutical Journal 15(2): 165-169, 2012

Ethical concerns with online direct-to-consumer pharmaceutical companies

2019 ◽  
Vol 46 (3) ◽  
pp. 168-171
Author(s):  
Henry Curtis ◽  
Joseph Milner
Keyword(s):  
Direct Contact ◽  
Conflicts Of Interest ◽  
Cost Effective ◽  
Pharmaceutical Companies ◽  
Prescription Medications ◽  
Ethical Concerns ◽  
Direct To Consumer ◽  
Alternative Method

In recent years, online direct-to-consumer pharmaceutical companies have been created as an alternative method for individuals to get prescription medications. While these companies have noble aims to provide easier, more cost-effective access to medication, the fact that these companies both issue prescriptions (via entirely online medical reviews that can have no direct contact between physician and patient) as well as distribute and ship medications creates multiple ethical concerns. This paper aims to explore two in particular. First, this model creates conflicts of interest for the physicians hired by these companies to write prescriptions. Second, the lack of direct contact from physicians may be harmful to prospective patients. After analysing these issues, this paper argues that there ought to be further consideration for regulation and oversight for these companies.

scholarly journals Efforts and Challenges paved by India to confront of Corona Virus (COVID-19)

2020 ◽  
Author(s):  
Mohammad Gayoor Khan ◽  
Umama Yezdani ◽  
Arghya Chakravorty ◽  
Tanvi Shukla
Keyword(s):  
Medical Science ◽  
Multiple Organ ◽  
Contact Tracing ◽  
Healthcare Sector ◽  
Pharmaceutical Companies ◽  
Multiple Organ Dysfunction ◽  
Capacity Strengthening ◽  
Government Administration ◽  
Laboratory Capacity ◽  
Clinical Conditions

The clinical range of Covid-19 is a respiratory route infection that varies from Asymptomatic to various clinical conditions such as respiratory failure to multiple organ dysfunction syndromes (MODS). Government administration officials are ramping up many efforts i.e prevention and containing the spread from escalating to the next level, raising the quarantine stations and increase in the laboratory capacity, strengthening surveillance, contact tracing using artificial intelligence (AI) via technology apps. India is Consequently facing many challenges to tackle the pandemic from shortage of medical supply to the devastation of the educational, transportation, job sectors, and healthcare sector, However, pharmaceutical companies taking center stage in the Covid-19 fight, Other pharmaceutical companies(low scale) in India are following suit during the Covid-19 pandemic and using their capabilities to lighten the burden of coronavirus, WHO recommends social distancing and country-wise lockdown are very essential to tackle the coronavirus, the GOI is scheming on how to get back to normalcy, with an actionable exit plan for the states to confront the coronavirus Bangladesh Journal of Medical Science Vol.19(0) 2020 p. S 88-S 92

scholarly journals Conflicts of Interest in International Human Drug Research and the Insufficiency of International Protections

2006 ◽  
Vol 32 (2-3) ◽  
pp. 351-364 ◽  
Author(s):  
Robert Gatter
Keyword(s):  
Drug Research ◽  
Conflicts Of Interest ◽  
Human Subjects ◽  
Private Investment ◽  
Pharmaceutical Products ◽  
Pharmaceutical Companies ◽  
Human Subjects Research ◽  
Drug Companies ◽  
The World ◽  
Financial Conflicts Of Interest

The world relies largely on private firms for the development of new medicine, and the system is efficient. Driven by the incentive to profit from sales of new pharmaceuticals, drug companies risk millions of dollars and years of work to shepherd basic scientific discoveries through laboratory and human testing in the hope of developing a marketable drug. For example, it is estimated that in 2002 alone, pharmaceutical companies invested $45 billion the development of new medicine worldwide.While the profit incentive generates such enormous private investment in human drug development, it also encourages firms to pose inappropriate risks to the safety of human subjects when speeding a new drug to the market. The risks posed by financial conflicts of interest associated with human subjects research on new pharmaceutical products are notable examples, both in the U.S. and internationally.

Sign in / Sign up

Export Citation Format

Share Document